Hussman Strategic Advisors’s Moderna MRNA Stock Holding History

Hussman Strategic Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,000	Closed	-$120K	–	297
2020 Q1	$120K	Buy	+4,000	New	+$92K	0.03%	261

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Hussman Strategic Advisors's MRNA Position: Q2 2020 in Review

Hussman Strategic Advisors sold out of Moderna (MRNA) in Q2 2020, closing a stake of 4,000 shares — an estimated $120K sold.

Hussman Strategic Advisors first reported a position in MRNA in Q1 2020 and held it in 1 quarter. The position peaked at $120K in Q1 2020. 489 funds tracked by Wall St. Rank hold MRNA as of Q2 2020.

Hussman Strategic Advisors reported no remaining Moderna position as of Q2 2020 after selling out during the quarter.
Hussman Strategic Advisors sold 4,000 Moderna shares in Q2 2020, an estimated $120K.
Hussman Strategic Advisors first reported a position in Moderna in Q1 2020 and held it in 1 quarter.
Hussman Strategic Advisors's Moderna position peaked at $120K in Q1 2020.
489 funds tracked by Wall St. Rank held Moderna as of Q2 2020.

Based on Hussman Strategic Advisors's 13F filing for Q2 2020, filed 31 Jul 2020.